Grifols (GIFLF) Interest Coverage Ratio (2010 - 2025)
Grifols' (GIFLF) quarterly Interest Coverage Ratio came in at 1988.8 in Q4 2025, down 19.13% on a YoY basis from 2459.19 in Q4 2024, and down 19.13% quarter-over-quarter from 1669.47 in Q4 2024.
Powered by 
Analysis
Grifols (GIFLF) Interest Coverage Ratio (2010 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Interest Coverage Ratio for 14 consecutive years, with 1988.8 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Interest Coverage Ratio fell 19.13% year-over-year to 1988.8; the trailing twelve-month figure through Dec 2025 stood at 36.92 (up 298.02% YoY), and the FY2025 full-year result was 1.99, down 19.13% from the prior year.
- Interest Coverage Ratio eased to 1988.8 in Q4 2025 per GIFLF's latest filing, from 1669.47 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 1.64 in Q4 2021 and bottomed at 1988.8 in Q4 2025.
- Historically, Interest Coverage Ratio has averaged 1219.97 across 3 years, with a median of 1669.47 in 2024.
- The sharpest annual moves came in 2021 and 2025: Interest Coverage Ratio advanced 19.04% in 2021, then declined 19.13% in 2025.
- Over 3 years, Interest Coverage Ratio stood at 1.64 in 2021, then slumped by 101962.41% to 1669.47 in 2024, then retreated by 19.13% to 1988.8 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1988.8, 1669.47, and 1.64 for Q4 2025, Q4 2024, and Q4 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 1,988.80 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -1,988.80 |
| Dec 31, 2024 | -1,669.47 |
| Dec 31, 2021 | -1.64 |
| Dec 31, 2020 | -2.02 |
| Dec 31, 2019 | 44.52 |
| Dec 31, 2018 | -0.75 |
| Jun 30, 2018 | -1.26 |
| Dec 31, 2017 | -3.05 |
| Jun 30, 2017 | 4.10 |
| Dec 31, 2016 | -7.60 |
| Sep 30, 2016 | 3.91 |
| Jun 30, 2016 | 3.60 |
| Dec 31, 2015 | 15.00 |
| Sep 30, 2015 | 4.09 |
| Jun 30, 2015 | 4.00 |
| Mar 31, 2015 | -3.89 |
| Dec 31, 2014 | 10.54 |
| Sep 30, 2014 | 3.98 |
| Jun 30, 2014 | 3.64 |
| Mar 31, 2014 | 3.48 |